CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Creative Medical Technology Holdings, Inc.

Equities

CELZ

US22529Y4089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-07-17 EDT			5-day change	1st Jan Change
3.665 ^USD	+3.53%		+3.51%	-20.50%

06-24	Creative Medical Successfully Generated Human Ipsc-Derived Islet Cells That Produce Human Insulin	RE
06-24	Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin	CI

Creative Medical Technology Holdings, Inc. announced that it expects to receive funding from PowerUp Lending Group, Ltd.

January 16, 2018

Creative Medical Technology Holdings, Inc. (OTCPK:CELZ) announced that it will receive $44,000 in funding on January 17, 2018. The company will issue convertible note in the transaction. The minimum investment accepted from any outside investor is $44,000. The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about Creative Medical Technology Holdings, Inc.

Creative Medical Successfully Generated Human Ipsc-Derived Islet Cells That Produce Human Insulin	06-24	RE
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin	06-24	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	03-22	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
Creative Medical Shares Rise 37% After FDA Authorization for CELZ-201	03-07	DJ
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access	03-07	CI
Creative Medical Technology Holdings Gets US FDA Orphan Drug Designation; Shares Rise	03-06	MT
Private Payrolls Data, Upcoming Powell Testimony Drive Higher Premarket Action for US Equity Futures	03-06	MT
Creative Medical Shares Rally Premarket on FDA Orphan Designation	03-06	DJ
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony	03-06	MT
Top Premarket Gainers	03-06	MT
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem	12-20	CI
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	11-14	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain	23-10-10	CI
Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem? (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain	23-09-19	CI
Top Premarket Gainers	23-09-13	MT
Top Premarket Gainers	23-08-21	MT
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	23-08-11	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Top Premarket Decliners	23-06-16	MT
Creative Medical Technology Holdings, Inc. announces an Equity Buyback for $2 million worth of its shares.	23-06-12	CI
Creative Medical Technology Holdings, Inc. authorizes a Buyback Plan.	23-06-11	CI
Creative Medical to Trade on 1-for-10 Reverse Stock-Split Basis Starting Monday	23-06-09	MT

Chart Creative Medical Technology Holdings, Inc.

Duration

Period

Chart Creative Medical Technology Holdings, Inc.

More charts

Company Profile

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.665 USD

Average target price

30 USD

Spread / Average Target

+718.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.	-20.50%	4.94M
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.24%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.99%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs